This suggests that VILIP3 may be a potential target for the treatment of AD, and there is a need for more comprehensive studies of the role and mechanism of VILIP3 in AD in the future, as well as the development of specific VILIP3 activators to better support clinical treatment. This evidence concerns the gene HPCAL1 and Alzheimer disease.